Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lipella Pharmaceuticals Inc (LIPO)

Lipella Pharmaceuticals Inc (LIPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lipella Pharmaceuticals Completes Dosing for First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals completes initial dosing in Phase 2a trial of LP-310 for Oral Lichen Planus, showing promising results.Quiver AI SummaryLipella Pharmaceuticals Inc. has announced the completion...

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Advances With Multiple Near-Term Catalysts and Strategic Focus on Rare Diseases

Lipella Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing and commercializing treatments for serious diseases with significant unmet needs.

LIPO : 2.63 (+8.68%)
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
CRDF : 2.45 (-2.00%)
LLY : 748.01 (-0.25%)
ABBV : 176.95 (+3.04%)
LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

/PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases...

LIPO : 2.63 (+8.68%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar